Vaccinex, Inc. (VCNX) stock
VCNXOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q4 FY2024, quarter ended Dec 31, 2024Last filing: 10-K on Apr 15, 2025
$1.00−0.01 (-0.99%)
Close on Oct 19, 2026Market cap $3.22MP/E –Yield –
Vaccinex r&d expenses
Research and development expenses are spending on new products and technology.
Vaccinex's R&D Expenses for the twelve months ending Dec 31, 2024 was $12.55M, down 24.3% year over year. For fiscal 2024 it was $12.55M, down 24.3% from the year before. The highest annual figure on record is $25.67M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $12.55M | -24.3% |
| FY2023 | Dec 31, 2023 | $16.57M | +18.6% |
| FY2022 | Dec 31, 2022 | $13.98M | -18.5% |
| FY2021 | Dec 31, 2021 | $17.16M | -20.4% |
| FY2020 | Dec 31, 2020 | $21.55M | -16.1% |
| FY2019 | Dec 31, 2019 | $25.67M | +14.8% |
| FY2018 | Dec 31, 2018 | $22.35M | +35.1% |
| FY2017 | Dec 31, 2017 | $16.55M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | $2.13M | -36.5% |
| Q3 FY2024 | Sep 30, 2024 | $3.17M | -27.3% |
| Q2 FY2024 | Jun 30, 2024 | $3.86M | -23.5% |
| Q1 FY2024 | Mar 31, 2024 | $3.38M | -11.3% |
| Q4 FY2023 | Dec 31, 2023 | $3.36M | -10.3% |
| Q3 FY2023 | Sep 30, 2023 | $4.36M | +27.0% |
| Q2 FY2023 | Jun 30, 2023 | $5.05M | +31.4% |
| Q1 FY2023 | Mar 31, 2023 | $3.81M | +28.5% |
| Q4 FY2022 | Dec 31, 2022 | $3.74M | -5.4% |
| Q3 FY2022 | Sep 30, 2022 | $3.43M | -5.5% |
| Q2 FY2022 | Jun 30, 2022 | $3.84M | -5.4% |
| Q1 FY2022 | Mar 31, 2022 | $2.97M | -46.2% |
| Q4 FY2021 | Dec 31, 2021 | $3.95M | -6.9% |
| Q3 FY2021 | Sep 30, 2021 | $3.63M | -50.5% |
| Q2 FY2021 | Jun 30, 2021 | $4.06M | -10.8% |
| Q1 FY2021 | Mar 31, 2021 | $5.51M | +1.9% |
| Q4 FY2020 | Dec 31, 2020 | $4.25M | -3.7% |
| Q3 FY2020 | Sep 30, 2020 | $7.33M | +12.1% |
| Q2 FY2020 | Jun 30, 2020 | $4.56M | -37.6% |
| Q1 FY2020 | Mar 31, 2020 | $5.41M | -27.0% |
| Q4 FY2019 | Dec 31, 2019 | $4.41M | -37.6% |
| Q3 FY2019 | Sep 30, 2019 | $6.54M | +23.1% |
| Q2 FY2019 | Jun 30, 2019 | $7.30M | +32.5% |
| Q1 FY2019 | Mar 31, 2019 | $7.41M | +66.4% |
| Q4 FY2018 | Dec 31, 2018 | $7.07M | +40.7% |
| Q3 FY2018 | Sep 30, 2018 | $5.31M | +23.8% |
| Q2 FY2018 | Jun 30, 2018 | $5.51M | +62.5% |
| Q1 FY2018 | Mar 31, 2018 | $4.45M | – |
| Q4 FY2017 | Dec 31, 2017 | $5.03M | – |
| Q3 FY2017 | Sep 30, 2017 | $4.29M | – |
| Q2 FY2017 | Jun 30, 2017 | $3.39M | – |
See a number that looks wrong?